

# Sarecycline: Rapid Improvement of Truncal Acne in Hispanic Male

Angela Yen Moore<sup>1,2</sup>, Stephen Moore<sup>1,3</sup>, Luke Moore<sup>1</sup>, Stephen K Tyring<sup>3</sup>

<sup>1</sup>Arlington Research Center, Arlington, TX, USA; <sup>2</sup>Baylor University Medical Center, Dallas, TX, USA

<sup>3</sup>Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA

## INTRODUCTION


- Acne vulgaris is a common disease of both males and females, usually manifesting initially during adolescence.
- 60-70% of patients present with acne on the trunk.<sup>1</sup>
- Since severity of truncal acne does not correlate with severity of facial acne, the psychosocial burden and physical pain and bleeding of truncal acne cannot be underestimated.<sup>2</sup>
- Antibiotics in the tetracycline family have been prescribed as acne treatments for many years.
- Sarecycline, a narrow-spectrum 3<sup>rd</sup> generation tetracycline-class antibiotic, was FDA approved for moderate-to-severe acne vulgaris in patients 9 years of age and older in October, 2018.
- Sarecycline exhibits potent anti-inflammatory activity, activity against *Cutibacterium acnes* and clinically relevant Gram-positive bacteria, but reduced activity against Gram-negative bacteria commonly found in the gut, may contribute to its favorable side effect profile.<sup>3</sup>
- Significant improvement in truncal acne, using IGA assessments, was reported with sarecycline in Phase 3 clinical trials.<sup>4,5</sup>

## CASE REPORT

- We present a 18-year-old Hispanic male with severe acne vulgaris on the trunk treated with sarecycline monotherapy for 3 months, and assessed IGA scores and lesion counts of the trunk, with objective photographs, at weeks 3, 6, 9 and 12.
- At baseline, the patient presented with severe acne vulgaris on the trunk, with 77 inflammatory lesions on the trunk.

## RESULTS

Figure 1: Inflammatory Lesions on Trunk



## RESULTS

Figure 2. Patient Photos of Back





Figure 3: IGA of Trunk



- At weeks 3, 6, 9, and 12, inflammatory lesions counts on the trunk decreased to 13 (83% reduction), 13 (83% reduction), 8 (90% reduction), and 7 (91% reduction), respectively.
- IGA score for the trunk decreased from IGA of 4 at baseline to 1 (almost clear) at week 12.
- No side effects of special interest for tetracycline-family antibiotics, including nausea, diarrhea, esophagitis, pseudotumor cerebri, blurry or double vision, dizziness, vertigo, or blue-gray pigmentation, were observed.

## CONCLUSIONS

- This case report confirms clinical observation of rapid improvement of truncal acne in Phase 3 clinical trials.

## CLINICAL IMPLICATIONS

- Oral sarecycline may offer a practical and convenient treatment for truncal acne, especially in areas where topical agents can be difficult to apply.

## REFERENCES

- Del Rosso JQ, Stein-Gold L, Lynde C, Tangheiti E, Alexis AF. Truncal Acne: A Neglected Entity. *J Drugs Dermatol*. 2019;18(12):205-1208.
- Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial and truncal acne on quality of life: A multi-country population-based survey. *JAAD International*. 2021;3:102-110. doi:10.1016/j.jdin.2021.03.002
- Bunick CG, Keri J, Tanaka SK, et al. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. *Antibiotics (Basel)*. 2021;10(4):439. doi:10.3390/antibiotics10040439
- Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: Results from two identically designed, phase 3, randomized, double-blind clinical trials. *Journal of drugs in dermatology: JDD*. 2018;17(9):987-996.
- Del Rosso JQ, Stein Gold L, Baldwin H, et al. Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials. *J Drugs Dermatol*. 2021;20(6):634-640. doi:10.36849/JDD.2021.6204

Disclosures: Investigator Initiated Trial Funds were received from Almirall, LLC.